



**M Opravil**

**Kontakt**

M Opravil

## Publikationen (17)

Young J, Bucher H, Battegay M, Hirschel B, Vernazza P, Bernasconi E, Cavassini M, Fux C, Rickenbach M, Böni J, Yerly S, Opravil M, Günthard H, Scherrer A, for the Swiss HIV Cohort Study. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. *HIV Med* 2010

Nguyen A, Hirschel B, Perneger T, Schmid P, Tarr P, Evison J, Opravil M, Battegay M, Bernasconi E, Schiffer V, Calmy A, Swiss HIV Cohort Study. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006. *HIV medicine* 2008; 9:142–50.

Bertschy S, Furrer H, Christen A, Chave J, Flepp M, Schmid P, Schiffer V, Bernasconi E, Cavassini M, Opravil M, Swiss HIV Cohort Study. Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2006; 12:666–71.

Wagels T, Amiet R, Battegay M, Guex A, Opravil M, Vernazza P, Swiss HIV Cohort Study Group. Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2004; 134:678–80.

Boubaker K, Francioli P, Rickenbach M, Opravil M, Egger M, Bernasconi E, Chave J, Boggian K, Hirschel B, Haensel A, Furrer H, Sudre P, Flepp M, Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis* 2001; 33:1931–7.

Bisset L, Opravil M, Grob P, Weber R, Dubs R, Vernazza P, Battegay M, Fischer M, Cone R, Swiss HIV Cohort Study. Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection. *Journal of acquired immune deficiency syndromes (1999)* 2001; 27:266–71.

Furrer H, Egger M, Flepp M, Rickenbach M, Boggian K, Schiffer V, Bucher H, Telenti A, Bernasconi E, Rossi M, Opravil M, Swiss HIV Cohort Study. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of *Pneumocystis carinii* pneumonia: prospective multicentre study. *AIDS* 2001; 15:501–7.

Rutschmann O, Perrin L, Leduc D, Fagard C, Bernasconi E, Malinverni R, Telenti A, Ledergerber B, Opravil M, Bucher H, Vernazza P, Hirschel B. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. *Swiss HIV Cohort Study. AIDS (London, England)* 2000; 14:2145–51.

Opravil M, Lüthy R, Roos M, Knuchel M, Huber W, Ott P, Bisset L, Lorenzi P, Bassetti S, Vernazza P, Fischer M, Cone R, Weber R. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. *Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999)* 2000; 23:17–25.

Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. *JAMA : the journal of the American Medical Association* 1999; 282:2220–6.

Zinkernagel C, Ledergerber B, Battegay M, Cone R, Vernazza P, Hirschel B, Opravil M. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. *Swiss HIV Cohort Study. AIDS (London, England)* 1999; 13:1587–9.

Weber R, Meyenberger C, Opravil M, Kaiser L, Briner J, Spycher M, Pfyffer G, Altwegg M, Zbinden R, Ledergerber B, Flepp M. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study. Archives of internal medicine 1999; 159:1473-80.

Furrer H, Flepp M, Rickenbach M, Vernazza P, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. The New England journal of medicine 1999; 340:1301-6.

Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza P, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.

Bisset L, Cone R, Huber W, Battegay M, Vernazza P, Weber R, Grob P, Opravil M. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:2115-23.

Rutschmann O, Perrin L, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:F71-7.

Rutschmann O, Yerly S, Perrin L, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Antiviral therapy 1998; 3 Suppl 4:65-7.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)